Disruptive Biomedical Technologies, Maximizing both Economical and Patient Benefits: What to do? How to do it?

01 October 2019

Boğaziçi-BME/Lifesci & Inovita & ISEK Joint Seminar

Disruptive Biomedical Technologies, Maximizing both Economical and Patient Benefits: What to do? How to do it? 

1 October 2019 (Tuesday); 13.00 – 14.00


Institute of Biomedical Engineering, Boğaziçi University Kandilli Campus, Istanbul 


Cengizhan Ozturk, MD, PhD

BME, Boğaziçi University ; Coordinator, Inovita & ISEK


About the Seminar:

First, a clearly personally biased definition of the disruptive biomedical technologies will be provided with a focus on sustainability of the health  care and democratization of advanced technologies. Some of the pertinent questions are: “Which technologies are technically/technologically/scientifically beyond the state of the art? Do they really increase the quality of life (of patients)? Do they simplify diagnosis and/or management of a particular disease? Do they save money and which ones will be accessible to all in need?” In the next part of the talk, our global health challenges will be reviewed, as well as our unique situation in Turkey. Looking from this broader perspective, we will proceed to a critical inward look towards what is being done at BU-BME, BU-LifeSci and its spinoff industrial interfaces: Inovita and ISEK (Istanbul health Industry Cluster). It is clearly an ongoing adventure, and there are lessons for all interested researchers, entrepreneurs, and even for administrators! At the end of the talk, a special call will be made for all new and prospective students to participate into our newly kicked-off industrial Ph.D. program focusing on biomedical technologies (https://bme.boun.edu.tr/node/1919).

About the Speaker: 

Dr. Ozturk received his M.D. from Marmara School of Medicine, Istanbul, in 1990. He proceeded with a Specialization in Physiology from Cerrahpasa Medical Faculty, Istanbul University, in 1994 and a Ph.D. at the School of Biomedical Engineering, Science and Health Systems, Drexel University, Philadelphia, in 1997. During 1997-2000, he worked as a postdoctoral research fellow at Medical Imaging Lab, Department of Biomedical Engineering, Johns Hopkins University. Since September 2000, he is working as a faculty member at the Institute of Biomedical Engineering (BME), Bogazici University, Istanbul (http://bme.boun.edu.tr). While at BME, Dr. Ozturk managed to hold a visiting research scientist position at Cardiac Interventions Program, NHLBI, NIH, for five years (2002-2008). His research at NHLBI focused on real-time MRI, XMR fusion and MR-guided medical interventions. Dr. Ozturk initially established Medical Imaging Laboratory (BUMIL) at BME, where on average 15-20 graduate-level BME students at any given time performed their research on a wide-gamut of medical imaging topics. BUMIL is now a virtual laboratory, bringing together all the BME labs which are actively doing research in any topic related to biomedical imaging. The newly established laboratory of Dr. Ozturk is XLAB (https://xlab.boun.edu.tr/) where the research focus is expanded to cover the development of novel medical imaging instruments.

Between 2008-2013, Dr. Ozturk coordinated a university-wide effort to establish a multidisciplinary research center focused on life sciences and health technologies, funded by the Turkish Ministry of Development. The Center for Life Sciences and Technologies of Bogaziçi University (BULifeSci,http://lifesci.boun.edu.tris now supported by over 50 faculty members from 13 academic departments/institutes. It is currently in its second expansion phase within the Kandilli Science and Technology Building of Bogazici University. BULifeSci’s already established national research infrastructures are: 1)Microsystem Based in vivo Device Development Laboratory with a dual-purpose clean room that combines MEMS capability with medical plastic/metal processing for development of novel interventional devices and sensors, 2) Small Animal Research Center (Vivarium) with transgenic capabilities – and with a plan to establish a spinoff infrastructure for small animal imaging, 3) currently expanding Test and Analysis Unit, reorganized both for industrial services and academic research, with a focus on material characterization (such as nanoparticles for smart drugs and implantable medical devices).

Since 2011, Dr. Ozturk is coordinating the Istanbul Cooperation Platform for Life Sciences and Technologies (Inovita), funded initially by Istanbul Development Agency (ISTKA). Main focus of Inovita is to create an environment to foster translational research and entrepreneurial activities in health technologies. Dr. Ozturk started to coordinate the establishment of health-tech incubator labs (BioCube) and several medtech/biotech pilot production facilities at Teknopark Istanbul. The outcome of all these BULifeSci university-industry coordination efforts was ISEK (Istanbul Health Industry Cluster, İstanbul Sağlık Endüstrisi Kümelenmesi, http://www.i-sek.org), which was established at the beginning of 2014, and - as of September 2019 - has over 180 companies (half of them startup and microSME’s),  17 university research center, more than 13 NGO’s and governmental agencies. ISEK received a special 5-year cluster support grant in May 2017 from Ministry of Industry and Technology.